Eli Lilly Raises 2026 Revenue Forecast as GLP-1 Drugs Fuel Record Growth

Eli Lilly beats Q2 estimates with revenue up 48% to $23B, driven by Mounjaro and Zepbound. Company raises full-year outlook to $85–87 billion.